These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Construction of IL-1Ra-HSA fusion protein and analysis of its bioactivity and pharmacokinetics]. Huang Y; Hu L; Yang YQ; Hu XP; Zhen YS; Liu MY Yao Xue Xue Bao; 2012 Sep; 47(9):1210-8. PubMed ID: 23227553 [TBL] [Abstract][Full Text] [Related]
24. Treatment of Periodontal Inflammation in Diabetic Rats with IL-1ra Thermosensitive Hydrogel. Liu Y; Liu C; Wang C; Zhang Q; Qu X; Liang C; Si C; Wang L Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430410 [TBL] [Abstract][Full Text] [Related]
25. The intratracheal administration of endotoxin and cytokines. III. The interleukin-1 (IL-1) receptor antagonist inhibits endotoxin- and IL-1-induced acute inflammation. Ulich TR; Yin SM; Guo KZ; del Castillo J; Eisenberg SP; Thompson RC Am J Pathol; 1991 Mar; 138(3):521-4. PubMed ID: 1825745 [TBL] [Abstract][Full Text] [Related]
26. Advances in immunotherapy delivery from implantable and injectable biomaterials. Leach DG; Young S; Hartgerink JD Acta Biomater; 2019 Apr; 88():15-31. PubMed ID: 30771535 [TBL] [Abstract][Full Text] [Related]
27. Interleukin-1 receptor antagonist: An alternative therapy for cancer treatment. Fang Z; Jiang J; Zheng X Life Sci; 2023 Dec; 335():122276. PubMed ID: 37977354 [TBL] [Abstract][Full Text] [Related]
28. Balance of interleukin-1 beta and interleukin-1 receptor antagonist in human periapical lesions. Shimauchi H; Takayama S; Imai-Tanaka T; Okada H J Endod; 1998 Feb; 24(2):116-9. PubMed ID: 9641143 [TBL] [Abstract][Full Text] [Related]
29. Is IL-1 a good therapeutic target in the treatment of arthritis? Burger D; Dayer JM; Palmer G; Gabay C Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):879-96. PubMed ID: 16980212 [TBL] [Abstract][Full Text] [Related]
30. Glomerular expression of interleukin-1 receptor antagonist and interleukin-1 beta genes in antibody-mediated glomerulonephritis. Tam FW; Smith J; Cashman SJ; Wang Y; Thompson EM; Rees AJ Am J Pathol; 1994 Jul; 145(1):126-36. PubMed ID: 8030744 [TBL] [Abstract][Full Text] [Related]
31. A comparative study of the inhibitory effects of interleukin-1 receptor antagonist following administration as a recombinant protein or by gene transfer. Gouze JN; Gouze E; Palmer GD; Liew VS; Pascher A; Betz OB; Thornhill TS; Evans CH; Grodzinsky AJ; Ghivizzani SC Arthritis Res Ther; 2003; 5(5):R301-9. PubMed ID: 12932294 [TBL] [Abstract][Full Text] [Related]
32. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Dinarello CA; Simon A; van der Meer JW Nat Rev Drug Discov; 2012 Aug; 11(8):633-52. PubMed ID: 22850787 [TBL] [Abstract][Full Text] [Related]
33. Is interleukin-1 a good target for therapeutic intervention in intervertebral disc degeneration: lessons from the osteoarthritic experience. Goupille P; Mulleman D; Chevalier X Arthritis Res Ther; 2007; 9(6):110. PubMed ID: 18086327 [TBL] [Abstract][Full Text] [Related]
34. Synthesis of interleukin-1 receptor antagonist by Thy-1+ and Thy-1- murine lung fibroblast subsets. Silvera MR; Phipps RP J Interferon Cytokine Res; 1995 Jan; 15(1):63-70. PubMed ID: 7648435 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage. Gueorguieva I; Clark SR; McMahon CJ; Scarth S; Rothwell NJ; Tyrrell PJ; Hopkins SJ; Rowland M Br J Clin Pharmacol; 2008 Mar; 65(3):317-25. PubMed ID: 17875190 [TBL] [Abstract][Full Text] [Related]
36. Alginate/chitosan microcapsules for in-situ delivery of the protein, interleukin-1 receptor antagonist (IL-1Ra), for the treatment of dextran sulfate sodium (DSS)-induced colitis in a mouse model. Cao J; Cheng J; Xi S; Qi X; Shen S; Ge Y Eur J Pharm Biopharm; 2019 Apr; 137():112-121. PubMed ID: 30779979 [TBL] [Abstract][Full Text] [Related]
37. Peripheral nerve regeneration is impeded by interleukin-1 receptor antagonist released from a polymeric guidance channel. Guénard V; Dinarello CA; Weston PJ; Aebischer P J Neurosci Res; 1991 Jul; 29(3):396-400. PubMed ID: 1833560 [TBL] [Abstract][Full Text] [Related]
38. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist. Cunha JM; Cunha FQ; Poole S; Ferreira SH Br J Pharmacol; 2000 Jul; 130(6):1418-24. PubMed ID: 10903985 [TBL] [Abstract][Full Text] [Related]
39. Expression and characterization of recombinant IL-1Ra in Aspergillus oryzae as a system. Mahmoudi Azar L; Karaman E; Beyaz B; Göktan I; Eyüpoğlu AE; Kizilel S; Erman B; Gül A; Uysal S BMC Biotechnol; 2023 Jun; 23(1):15. PubMed ID: 37340430 [TBL] [Abstract][Full Text] [Related]
40. Human recombinant interleukin-1 receptor antagonist (hrIL-1ra) enhances the stimulatory effect of interleukin-2 on natural killer cell activity against MOLT-4 target cells. Conti P; Barbacane RC; Panara MR; Reale M; Placido FC; Fridas S; Bongrazio M; Dempsey RA Int J Immunopharmacol; 1992 Aug; 14(6):987-93. PubMed ID: 1428372 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]